Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL)Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 studyPrioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2...

Related Keywords

,Adicet Bio ,Janhavi Mohite ,Chen Schor ,Anne Bowdidge ,International Conference On Molecular ,Society For Immunotherapy Of Cancer ,Drug Administration ,Development For Solid Tumors ,Adicet Bio Inc ,Development Rd Expenses ,Nasdaq ,Stern Investor Relations Inc ,New Drug Application ,Chief Executive Officer ,Operational Highlights ,International Conference ,Molecular Targets ,Third Quarter ,Private Securities Litigation Reform Act ,Comprehensive Income ,Investor Relations ,